Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05726526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

Study acronym: VIEWER
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: Mar 30, 2026 to Mar 30, 2027
    • Study completion date: Mar 30, 2026 to Mar 30, 2028
    v6
  3. Primary completion date: Mar 30, 2025 to Mar 30, 2026
    • Study sites: 3 to 5
    • Eligibility criteria expanded, about 1 word
    v5
  4. Study sites: 1 to 3v4
  5. Primary completion date: Jun 30, 2025 to Mar 30, 2025
    • Study completion date: Jun 30, 2025 to Mar 30, 2026
    • Secondary endpoints: details revised at 10 of 10 entries
    • Study description expanded, about 4 words
    v3
  6. Secondary endpoints revised (10)
    • Study description expanded, about 33 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Trial Details
NCT Number NCT05726526
Lead Sponsor University of Manitoba
Conditions
(from sponsor)		 Chronic Kidney Disease Stage 5, End Stage Renal Disease
Related terms Kidney Failure, Chronic, Renal Insufficiency, Chronic
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov